Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Share-based Compensation (2024 - 2025)

Historic Share-based Compensation for Prelude Therapeutics (PRLD) over the last 2 years, with Q3 2025 value amounting to $2.4 million.

  • Prelude Therapeutics' Share-based Compensation fell 5911.24% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.8 million, marking a year-over-year change of. This contributed to the annual value of $21.3 million for FY2024, which is 1667.32% down from last year.
  • Per Prelude Therapeutics' latest filing, its Share-based Compensation stood at $2.4 million for Q3 2025, which was down 5911.24% from $3.8 million recorded in Q2 2025.
  • Over the past 5 years, Prelude Therapeutics' Share-based Compensation peaked at $6.1 million during Q2 2024, and registered a low of $2.4 million during Q3 2025.